Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.

Molecular cancer - 31 May 2014

Zheng Tongsen, Yin Dalong, Lu Zhaoyang, Wang Jiabei, Li Yuejin, Chen Xi, Liang Yingjian, Song Xuan, Qi Shuyi, Sun Boshi, Xie Changming, Meng Xianzhi, Pan Shangha, Liu Jiaren, Jiang Hongchi, Liu Lianxin

Abstract excerpt

BACKGROUND: Arsenic trioxide has been demonstrated as an effective anti-cancer drug against leukemia and solid tumors both in vitro and in vivo. However, recent phase II trials demonstrated that single agent arsenic trioxide was poorly effective against hepatocellular carcinoma (HCC), which might be due to drug resistance. METHODS: Mutation detection of p53 gene in arsenic trioxide resistant HCC cell lines was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Epithelial-Mesenchymal Transition

Share to Imidazoles

Share to Neoplasm Transplantation

Share to Oxides

Share to Tumor Protein p73

Source

Open in PubMed Open full text

Identifiers

PMID: 24884809
DOI: 10.1186/1476-4598-13-133
PMCID: PMC4046148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.PMID 24884809Read ↗

The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cellsSemantic proximity Read ↗

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancerSemantic proximity Read ↗

miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.Semantic proximity Read ↗

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.Semantic proximity Read ↗

A study on the anti-tumor effect and mechanism of arsenic trioxide on lung adenocarcinomaSemantic proximity Read ↗

Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73.Semantic proximity Read ↗

Combination of arsenic trioxide and apatinib synergistically inhibits small cell lung cancer by down-regulating VEGFR2/mTOR and Akt/c-Myc signaling pathway via GRB10Semantic proximity Read ↗

Combination of Arsenic trioxide and Apatinib Synergistically Inhibits Small Cell Lung Cancer by Down-Regulating VEGFR2/mTOR and Akt/c-Myc Signaling Pathway via GRB10Semantic proximity Read ↗

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell SelectivitySemantic proximity Read ↗

Overexpression of the metastasis-associated gene MTA3 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.Semantic proximity Read ↗

ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamicsSemantic proximity Read ↗

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.